Evidence map›Paper›PMID 40756112›Full record

ArticleFrontiers in oncology2025

Case Report: A successful multidisciplinary approach to doxorubicin extravasation from a PICC-port in a patient with breast cancer.

Concetta Calabrò, Serena Iacovelli, Giuseppe De Palma, Giuseppe Carravetta, Domenica Garofalo, Francesco Giotta, Agnese Latorre, Patrizia Nardulli, Cosmo Maurizio Ressa, Elsa Vitale and 2 more

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Concetta Calabrò *Pharmacy Unit, IRCCS Istituto Tumori "Giovanni Paolo II" Bari, Bari, Italy.
Serena Iacovelli *Pharmacy Unit, IRCCS Istituto Tumori "Giovanni Paolo II" Bari, Bari, Italy.
Giuseppe De PalmaInstitutional BioBank, Experimental Oncology and Biobank Management Unit, IRCCS Istituto Tumori "Giovanni Paolo II" Bari, Bari, Italy.
Giuseppe CarravettaAnaesthesia, Resuscitation and Postoperative Intensive Care Unit, IRCCS Istituto Tumori "Giovanni Paolo II" Bari, Bari, Italy.
Domenica GarofaloAnaesthesia, Resuscitation and Postoperative Intensive Care Unit, IRCCS Istituto Tumori "Giovanni Paolo II" Bari, Bari, Italy.
Francesco GiottaMedical Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II" Bari, Bari, Italy.
Agnese LatorreMedical Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II" Bari, Bari, Italy.
Patrizia NardulliPharmacy Unit, IRCCS Istituto Tumori "Giovanni Paolo II" Bari, Bari, Italy.
Cosmo Maurizio RessaPlastic and Reconstructive Surgery Unit, IRCCS Istituto Tumori "Giovanni Paolo II" Bari, Bari, Italy.
Elsa VitaleScientific Directorate, IRCCS Istituto Tumori "Giovanni Paolo II" Bari, Bari, Italy.
Valerio De SantisPlastic and Reconstructive Surgery Unit, IRCCS Istituto Tumori "Giovanni Paolo II" Bari, Bari, Italy.
Giovanni MastrandreaAnaesthesia, Resuscitation and Postoperative Intensive Care Unit, IRCCS Istituto Tumori "Giovanni Paolo II" Bari, Bari, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Infusion of chemotherapy drugs through central venous catheters in the bloodstream facilitates direct access to disseminated cancer sites to interrupt the growth and/or spread of abnormal cells. To represent the significance of a rapid, multidisciplinary intervention codified by a hospital-adopted procedure for the treatment of this specific type of extravasation. Methods: A case of a 63-year-old female patient with no comorbidities but overweight who was admitted to our hospital in 2023 was discussed. The oncologist requested the placement of a long-term central venous access for chemotherapy, expected to last at least 5-6 months. This case report describes a massive anthracycline extravasation through a PICC-port. Such a serious complication requires not only the prompt administration of dexrazoxane but, more importantly, a multidisciplinary approach. Without comprehensive and timely intervention, the patient would have likely lost the upper limb. Clinical implications: Following the surgical and pharmacological treatment, the patient achieved a restoration of normal limb function, thus resuming all regular activities. This outcome was made possible primarily due to the timely and professional intervention of the multidisciplinary team, which minimized the severe complications that doxorubicin extravasation can cause. Tunneling of the catheter, which moves the extravasation site (port pocket) away from the venipuncture site, is equally important. Another noteworthy element is the resumption of chemotherapy treatment, which might have been interrupted due to the severe complication resulting from the extravasation.

Indexed as

breast cancerdoxorubicin extravasationintravenous chemotherapy drugslong-term central venous accessmultidisciplinary interventionnecrosisPICC-PORT

Identifiers

PMID40756112
PMCPMC12313700

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.